 
Revance Therapeutics, Inc.  Confidential  i A PROSPECTIVE, RANDO MIZED, DOUBLE -
BLINDED, PLACEBO -CONTROLLED TRIAL OF 
DAXIBOTULINUMTOXINA FOR INJECTION 
FOR THE MANAGEMENT O F PLANTAR 
FASCIITIS  
Protocol Number: 1720201  
National Clinical Trial (NCT) Identified Number: [STUDY_ID_REMOVED]   
Sponsor: Revance Therapeutics, Inc . 
Version Number: 4.0 
14 Dec 2017  
 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201 14 Dec 2017  
Revance Therapeutics, Inc. Confidential  ii 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201 14 Dec 2017  
Revance Therapeutics, Inc. Confidential  iii 

 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  ix INVESTIGATOR’S AGREEMENT  
I have carefully read the protocol entitled: “ A Prosp ective, Rando mized, Double-Blind ed, Pla cebo-
Controll ed Trial  of Da xibotulinu mtoxinA for Inj ection for the Manag ement of Plantar Fas ciitis” and,  
I will provide copi[INVESTIGATOR_18280], any subsequent protocol amendments and access to all information 
provided by [CONTACT_309867]. I will discuss this material with them 
to ensure that they are fully informed about the investigational drug and the trial protocol.  
I agree to co nduct this clinical trial according to the attached protocol, in compliance with all applicable 
laws and regulations, and in accordance with the ethical principles stipulated in the Declaration of 
Helsinki.  
 
 
 
_____________________________________________ ________  
Investigator Signature   
____________________________  
Date  
 
_____________________________________________________  
Printed Name   
 
_____________________________________________________  
Institution Name   
 
_____________________________________________________  
Address   
 
_____________________________________________________  
City, State, Postal Code, Country   
____________________________  
Phone Number  
 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential  x Table of Contents 
STATEMENT OF COMPLIANCE ..............................................................................................................  1 
1 PROTOCOL SUMMARY ................................................................................................................ 2 
1.1 Synopsis ................................................................................................................................... 2 
  
  
2 INTRODUCTION ............................................................................................................................. 7 
  
  
  
  
  
  
  
  
  
  
  
  
  12 
3 OBJECTIVES AND ENDPOINTS ................................................................................................. 14 
4 STUDY DESIGN ............................................................................................................................ 15 
4.1 Overall Design ....................................................................................................................... 15 
  
  
 5 
4.5 Duration of Trial .................................................................................................................... 15 
  
4.7 End of Study Definition .........................................................................................................  16 
5 STUDY POPULATION .................................................................................................................. 17 
5.1 Inclusion Criteria ................................................................................................................... 17 
5.2 Exclusion Criteria .................................................................................................................. 17 
5.3 Lifestyle Considerations ........................................................................................................ 18 
  
5.4 Screen Failures....................................................................................................................... 19 
5.5 Strategies for Recruitment and Retention .............................................................................. 19 
  
  
  
  
  
  
  
  
  

 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential  xi   
  
  
 5 
6.6 Concomitant Therapy ............................................................................................................  25 
6.6.1 Rescue Medicine .................................................................................................. 26 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ................................................................................................... 27 
7.1 Discontinuation of Study Intervention ................................................................................... 27  
7.2 Early Discontinuation/Withdrawal Procedures ..................................................................... [ADDRESS_769129] to Follow- Up .................................................................................................................. 27  
8 STUDY ASSESSMENTS AND PROCEDURES .......................................................................... 29 
8.1 Study Assessments ................................................................................................................. 29 
8.1.1 Screening Visit ..................................................................................................... 29 
8.1.2 Injection Visit ...................................................................................................... 29 
8.1.3 Follow-Up Visits.................................................................................................. 30  
8.2 Efficacy Assessments ............................................................................................................ 31 
8.3 Safety and Other Assessments ............................................................................................... 32 
8.4 Adverse Events and Serious Adverse Events ........................................................................ 34 
8.4.1 Definition of Adverse Events (AE)...................................................................... 34 
8.4.2 Definition of Serious Adverse Events (SAE) ...................................................... [ADDRESS_769130] Trial Serious Adverse Events ................................................. 38 
  
8.4.11 Reporting of Pregnancy ....................................................................................... 40 
8.5 Unanticipated Adverse Events ............................................................................................... 40  
8.5.1 Definition of Unanticipated Adverse Events ....................................................... 40  
8.5.2 Unanticipated Adverse Event Reporting ............................................................. 40 
8.5.3 Reporting Unanticipated Adverse Events to Participants .................................... 41 
9 STATISTICAL CONSIDERATIONS ............................................................................................ 42 
9.1 Statistical Hypothesis ............................................................................................................. 42 
9.2 Sample Size Determination ................................................................................................... 42  
9.3 Populations for Analyses ....................................................................................................... 42 
9.4 Statistical Analyses ................................................................................................................ 42 
9.4.1 General Approach ................................................................................................ 42  
9.4.2 Analysis of the Primary Efficacy Endpoint(s) ..................................................... 43 
  
9.4.4 Safety Analyses.................................................................................................... 43 
9.4.5 Baseline Descriptive Statistics ............................................................................. 43 
  

 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential  xii   
  
  
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS .................. 45 
10.1 Regulatory, Ethical, and Study Oversight Considerations .....................................................  45 
10.1.1 Informed Consent Process ................................................................................... 45 
10.1.2 Study Discontinuation and Closure ..................................................................... 46  
  
  
  
10.1.6 Safety Monitoring/Data MAnagement Committee .............................................. [ADDRESS_769131] Keepi[INVESTIGATOR_007] .................................................................... 48 
10.1.10 Protocol Deviations.............................................................................................. 50 
  
  
10.2 Additional Considerations ..................................................................................................... 51 
10.2.1 Ethics and Responsibility ..................................................................................... 51  
  
10.3 Abbreviations ......................................................................................................................... 53 
  
  
  
  
  
  
  
  
 
 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  1 STATEMENT OF COMPLIA NCE  
 
The trial will be conducted in accordance with International Council for  Harmonisation Good Clinical 
Practice (ICH GCP) and  applicable [LOCATION_002] (US) Code of Federal Regulations (CFR ) Terms and 
Conditions of Award. The Principal Investigator [INVESTIGATOR_7433], or changes to the 
protocol will tak e place without prior agreement from the Investigational New Drug (IND) sponsor, 
funding agency and documented approval from the Institutional Review Board (IRB), except where 
necessary to eliminate an immediate hazard(s) to the trial participants. All per sonnel involved in the 
conduct of this study have completed Human Subjects Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to th e IRB for review and approval. Approval of both the protocol and the consent form must 
be obtained before any participant is en rolled. Any amendment to the protocol will require review and 
approval by [CONTACT_234123]. All changes to the consent fo rm 
will be IRB approved; a determination will be made regarding whether a new consent needs to be 
obtained from participants who provided consent, using a previously approved consent form.  
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 2 1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  A Prospective, Randomized, Double -Blinded, Placebo -Controlled Trial of 
DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis  
Study Des cription : Treatment with DaxibotulinumtoxinA for Injection (Daxi for Injection) of 
plantar fascia and plantar muscles combined with transient and selective 
partial paralysis of gastrocnemius/s oleus complex (dysfunction) and a 
simple home program and inexpensive splinting will ameliorate signs and 
symptoms of plantar fasciitis; will improve function, and will optimize 
health related quality of life.  
Objectives:  
 Primary Objective:  
 To compare t he safety and efficacy of DaxibotulinumtoxinA for 
Injection versus placebo for managing plantar fasciitis  
   
  
 
   
  
 
  
  
 
  
 
  
 
  
 
 
  
 
Study Population:  Male and female adult subjects who have plantar fasciitis that has not 
responded to conservative treatment modalities.  
Phase:  2  
Description of 
Sites /Facilities  
Enrolling Participants:  Up to 5 sites in the [LOCATION_002] (US) will participate in the study.  
Approximately 60 subjects will be enrolled.  
 
  
 
 
 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 3  
 
 
 
 
 
 
 
Study Duration:  Approximately eight (8) months  
Participant Duration:  The study duration for each participant is up to approximately five (5) 
months (up to four [4] weeks for Screening, a single day of Treatment, and 
up to 16 weeks of Follow -up). 
  

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 4 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 5 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 6 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 7 2  INTRODUCTION  

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 8 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 9 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 10 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 11 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 12 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 13 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 14 3 OBJECTIVES AND ENDPO INTS  
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINT S 
Primary    
To compare the safety and efficacy 
of DaxibotulinumtoxinA for 
Injection versus placebo for 
managing plantar fasciitis   Reduction in the visual analog 
scale (VAS) for pain for the foot at 
Week 8  Clinically relevant 
outcome measure  for 
this indication  
   
 
 
    
 
 
  
 
 
  
 
 
  
 
 
  
  
 
 
    
 
 
 
      
 
  
 
 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 15 4 STUDY DESIGN  
4.1 OVERALL  DESIGN  
The study is designed  as a prospec tive, randomized, placebo-controlled, double-blinded clinical trial to 
compare DaxibotulinumtoxinA for Injection and placebo injections for the management of plantar 
fasciitis signs and symptoms. 
4.5 DURATION OF TRIAL  
The study duration for each participant is up to approximately five (5) months (up to four [4] weeks for 
Screening, a single Injection day, and up to 16 weeks of Follow-up). 
 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version [ADDRESS_769132] meet the following inclusion criteria: 
1. Written informed consent, including authorization to release health information 
2. Male or female subjects 18 to 65 years of age with diagnosis of unilateral plantar fasciitis by 
[CONTACT_26853]/or ultrasonography 
3. Unilateral plantar fasciitis as defined as no symptoms or signs in the contralateral foot and no 
sought medical attention in the contralateral foot within three (3) months of diagnosis 
4. Persistent heel pain for more than three (3) months (such as pain with walking, pain 
interfering with quality of life, pain > 45/100 on the VAS for pain in the morning) 
  
 
 
  
 
 
 
  
  
 
  
 
Subjects will not be enrolled if they meet any of the following exclusion criteria: 
1. Previous injections of botulinum toxins in the lower extremities or feet 
2. Entrapment of the posterior tibial, lateral plantar, or medial plantar nerve (local nerve 
entrapment) 
3. Fixed hindfoot varus 
4. Posterior tibial tendon dysfunction 
5. Severe pes planus 
6. Midfoot collapse 
7. Significant talar or navicular callus 
8. Tarsal coalition or rigid flatfoot 
9. Systemic disease associated with foot pain 
10. Sciatica 
11. Severe osteoarthritis of the forefoot, midfoot, or ankle 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 18 12. Use of antibiotics that may interfere with neuromuscular junction function, for example, 
aminoglycoside antibiotics (e.g., gentamicin sulfate, fradiomycin sulfate), polypeptide 
antibiotics (e.g., polymixin B sulfate), tetracycline antibiotics, and lincomycin antibiotics, 
except for those contained in topi[INVESTIGATOR_166464], three (3) days prior to treatment and three 
(3) days post-treatment  
13. Peripheral vascular disease 
14. Rheumatoid arthritis 
15. Insulin dependent diabetes mellitus 
16. Previous surgery on the midfoot or hindfoot 
17. Hypertonicity 
18. Neuromuscular disease 
19. Systemic muscle weakness 
20. Fibromyalgia 
21. Allergy or hypersensitivity to any components of the study treatments 
22. Comorbidities that confound the evaluation of the feet 
  
 
 
 
  
  
 
  
 
  
 
 
  
  
  
 
 
 
5.[ADDRESS_769133] will be a person from whom informed consent is obtained and is documented in 
writing (i.e., subject signs an informed consent form), but who does not meet the study eligibility 
requirements.  
5.[ADDRESS_769134] not responded to 
conservative treatment modalities for three (3) months as per the PI’s discretion will be enrolled in these 
clinical trials. 
All subjects who p resent with plantar fasciitis who me et the study inclusion /exclusion criteria found in 
Sections 5.1 and 5.2 will be asked to participate in the study. If subjects agree to par ticipate and provide 
informed consent, they will be enrolled in the study a nd randomized to one (1) of the two (2) stud y 
treatments, DaxibotulinumtoxinA for Injection or placebo. 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment [ADDRESS_769135] recruiting materials is provided to all sites. In addition , selected Clinical Research 
Organization (CRO) is supporting si tes in managing subject recruitment.  
Subject retention will include regular study visits with the Investigator and site staff. A minimal 
acceptable stipend is provided to enrolled subjects for travel and time. Selected CRO will also work with 
Sponsor in d evelopi[INVESTIGATOR_585002].  
 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 21 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 22 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 23 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 24 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 25 6.6 CONCOMITANT THERAPY  
Concomitant medications are any prescription or over-the-counter preparations used by [CONTACT_585004]. Use of concomitant medications will be recorded on the Concomitant 
Medications case report form (CRF) beginning at the Screening Visit until the Week 16/Early 
Termination visit. The dose and dosing regimen of all prescription and non-prescription therapi[INVESTIGATOR_78611], including herbs, vitamins, or other nutritional supplements administered will be 
documented. 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment [ADDRESS_769136](s) may withdraw from the study at  any time if rescue medication is required .  
 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  27 7 STUDY INTERVENTION  DISCONTINUATION  AND PARTICIPANT  
DISCONTINUATION /WITHDRAWAL  
7.1 DISCONTINUATION  OF STUDY INTERVENTIO N 
Study s ubjects will receive a one (1) time only treatment for this study. Discontinuation of study 
treatment is not applicable. However, subjects may choose to discontinue their participation in the follow -
up phase at any time.  Refer to Early Discontinuation/Withdrawal Procedures, Section 7.2 , for more 
details.  
If a clinically significant finding is identified (including, but not limited to changes from b aseline) after 
enrollment, the I nvestigator or qualified designee will determine if any change in participant management 
is needed. Any new clinically relevant finding will be reported as an adverse event (AE).  
7.2 EARLY DISCONTINUATIO N/WITHDRAWAL PROCEDU RES  
A subject may voluntarily withdraw from study participation at any time. If the subject withdraws consent 
and discontinues  from the trial, the Investigator will attempt to determine the reason for discontinuation 
and record the reason in the subject’s trial records and on the case report form (CRF). If a subject 
withdraws consent because of an AE, that AE should be indicated as the reason for withdrawal. In the 
event of early discontinuation, (i.e., prior to the Final Evaluation) and whenever possible, the subject 
should be asked to return to the trial center to complete the assessments specified in the Week 16/Early 
Terminati on visit. Subjects who withdraw from the trial will not be replaced.  
If at any time during the trial, the Investigator determines that it is not in the best interest of the subject to 
continue, the subject will be discontinued from participation. The Investigator can discontinue a subject 
from study participation at any time if medically necessary or if the subject has failed to follow trial 
procedures or to keep follow -up appointments. Appropriate documentation in the subject’s trial record 
and CRF re garding the reason for discontinuation must be completed. Prior to discontinuing a subject 
from study participation, the Investigator will discuss his/her intentions with the Medical Monitor or 
designee.  
All subjects who fail to return to the trial center for the required follow -up visits will be contact[CONTACT_245732](s) why the subject failed to return for the necessary visit or elected to 
discontinue from the trial. If a subject is unreachable by [CONTACT_34675] a minimum of two (2) 
documented attempts (one [1] attempt on two [2] different days), a registered letter will be sent requesting 
that contact [CONTACT_78636].  
Revance has the right to terminate or to stop the trial at any time. Should this be necessary, both Rev ance 
and the Investigator will ensure that proper study discontinuation procedures are completed  
7.[ADDRESS_769137] be taken if a participant fails to return to the clinic for a required study visit:  
DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  28  The site will attempt to contact [CONTACT_19423](s) and counsel the 
participant on the impo rtance of maintaining the assigned visit schedule and ascertain if the 
participant wishes to and/or should continue in the study.  
 Before a participant is  deemed lost to follow -up, the I nvestigator or designee will make every 
effort to regain contact [CONTACT_4490] t he participant (where possible, three (3) telephone calls and, if 
necessary, a certified letter to the participant’s last known mailing address or local equivalent 
methods). These contact [CONTACT_13140]’s medical record or  
study file.  
 Should the participant continue to be unreachable, he or she will be considered to have withdrawn 
from the study with a primary reason of lost to follow -up. 
 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version [ADDRESS_769138] be obtained prior to conducting screening 
procedures.  Refer to Section 1.3 Schedule of Assessments , for activities to be performed. 
After the informed consent is obtained, the following procedures will be completed: 
 Physical examination 
 Foot and Ankle Examination of both feet (including range or motion and motor strength) 
 Collect vital signs (blood pressure [BP], pulse, tempera ture), weight, and height 
 Collec t blood samples for clinical laboratory (chemistry, hematology, urinalysis),  
 
 Collect ECG if not done within the last six (6) months 
 Collect X-rays if not done within the last six (6) months 
 Collec t concomitant medications/therapi[INVESTIGATOR_014], medical history information 
 VAS for pain for the foot to be completed by [CONTACT_585005]. L. Andrew Koman at Wake Forest Baptist Medical 
Center (WFBMC) to document a visual insp ection of the foot as well as a thorough foot examination. 
Results from clinical laboratory tests and cardiologist-interpreted ECG must be obtained, reviewed, and 
signed by [CONTACT_737]. Any abnormal results must be determined to be not clinically significant by [CONTACT_399418]. Any WOCBP having a positive pregnancy test pre-treatment will not 
be treated. 
8.1.2  INJECTION VISIT 
The following procedures will be completed pre-treatment :  
 Physical examination 
  
 Collect vital signs (blood pressure [BP], pulse, tempera ture) and weight 
    
  
   
  

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 30   
  
   
  
  
 
 Confirm subject eligibility.  
 
 
 
 
 
  
   
 
 
 
8.1.3  FOLLOW-UP VISITS  
Subjects will be evaluated five (5) times after their injection at  Weeks 1, 2, 4, 8, and 16 or any time 
subjects terminate prematurely. Acceptable study visit windows can be ±3 days. The following 
procedures will be completed at each follow-up visits:  
  
  
 Collect vital signs (blood pressure [BP], pulse, tempera ture) and weight 
  
 
  
   
  
  
  
   
  
  
 Collect concomitant medications/therapi[INVESTIGATOR_585003](s) 
 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  31  
Variation from  Scheduled Visit Days  
To allow for scheduling flexibility, limited variation will be permitted from the specified time of each 
visit as in table  shown below.   
Allow ed Variation from Scheduled Visit Days  
Scheduled Visit  Allowed Variation  
Weeks 1, 2, 4, 8, 16  +/- 3 days  
8.2 EFFICACY ASSESSMENTS  
Visual Analog Scale  (VAS) for Pain:  The pain VAS is a  continuous sc ale self-compl eted by [CONTACT_585006] a horizontal (HVAS) or  vertical (VVAS) lin e, usually 10 centimet ers (100 mm) 
in length, anchored by [CONTACT_1192] ( 2) verbal descriptors, one (1)  for each symptom e xtreme. Instru ctions, time  
period for reporti ng, and verbal descriptor anchors have varied wid ely in the  literature depending on 
intended use  of the  scale. 
For pain int ensity, the sc ale is most common ly anchored by “no pain” (score of 0) and “pain as b ad as it 
could be”  or “wo rst im aginable  pain” (score of 100 [100-mm s cale]). The respond ent is asked to place a 
line perpendicul ar to the VAS line at the point that represents their  pain intensi ty. 
(http://onlin elibrary.wiley.com/doi/10.1002/a cr.[ZIP_CODE]/full)   
American Orthopaedic Foot and Ankle Score (AOFAS):  The American Ac ademy of Orthop aedic 
Surgeons developed s everal mus culosk eletal outcom es instrum ents to collect subject b ased data to use  to 
assess the  effectiveness of tr eatments and to stu dy the clinical outcomes of  the treatments. The  AOFAS 
foot and ankle qu estionn aire was designed for  use in subjects  [ADDRESS_769139] ass essments of foot and ankle conditions and improv ements r esulting  from tr eatments. 
Disability indices for the lo wer limb core, global foot and  ankle function, and shoe comfo rt can be 
evaluated using  this instrum ent. The questionn aire requires about 10  minutes to complet e. 
Foot and Ankle Disability Index (FADI):  The FADI  contains 34 qu estions divided into two (2) 
subsc ales: the Foot and  Ankle  Disability Index and the Foot Ankle Disability Index Sport (M artin, 1999 ). 
Each of the questions is sco red using a five-point  Likert Scale from 0 (unable to do) to 4 (no di fficulty at 
all). The FADI was designed to coll ect info rmation f rom subjects re garding their functional limitations 
related to th eir feet and  ankles. The FA DI Sports module is a popul ation sp ecific subscale designed for 
athletes. The  questionn aire requires five (5)  to seven (7) minutes to compl ete. 
The Patient Reported Outcom es Me asurement  Information System (PROM IS): The PROMIS is a 
system of h ighly reliable, precise m easures of subject –reported health st atus for physical, ment al, and 
social well–being (http://ww w.nihpr omis.or g/). PRO MIS tools  measure what subjects a re able to do a nd 
how th ey feel by [CONTACT_585007].  PRO MIS measures can be used across a wide  variety of chronic  
diseases and conditions in clinical studies of the effectiveness of t reatment. 
Plantar fasciitis pain and disability scale (PFPS):  The PFPS is a survey that includes a series of 
key questions that relate to symptoms and control questions for plantar fasciitis 
(https://faoj.files.wordp ress.com/2009/05/pain_scale_for_plantar_fasciiits.pdf ). The PFPS also includes 
the VAS for pain and questions to measure the effect the pain has on their activities of daily living. 
This survey was designed to create a more descriptive, exclusive analysis for plantar fasciitis and 
has been shown to effectively discriminate pain that is unique to plantar fasciitis versus heel pain 
caused by [CONTACT_585008] . 
 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  32 8.3 SAFETY AND OTHER ASSESSMENTS  
Physical examination : A full physical examination, in addition to vital signs, including neurological 
examination of the face, general appearance, skin, neck (including thyroid), eyes, ears, nose, throat, heart, 
lungs, abdomen, lymph nodes, and extremities will be conducted at Screening and pre -treatment at the 
Injection visit. At visits post -treatment, the physical examination may be abbreviated, as deemed 
medically appropriate at the discretion of the Investigator. Significant physical examination findings that 
are present pri or to investigational product administration are to be included on the Medical History page.  
Significant physical examination findings which meet the definition of an adverse event will be recorded 
on the adverse event page post -treatment .  
Pregnancy Testi ng: All WOCBP will have a SPT at the Screening and at Week 16/Early Termination 
visits and UPT at Injection visit pre -treatment. If any result is positive prior to treatment, the subject will 
not be allowed to participate. The results of the UPTs for WOCBP  will be evaluated at the trial center.  
WOCBP must use an effective method of birth control during the course of the trial, such as the oral 
contraceptive pi[INVESTIGATOR_4382], injection, implant, patch, vaginal ring, intrauterine coil, intrauterine device, tubal 
ligatio n, barrier method used WITH  an additional form of contraception (e.g., sponge, spermicide or 
condom), abstinence, no heterosexual intercourse, or has a vasectomized partner. A female is considered 
to be of childbearing potential UNLESS she is post -menopaus al (no menses for 12 consecutive months) 
or without a uterus and/or both ovaries.  
Before enrolling WOCBP in this clinical trial, Investigator must review guidelines about study 
participation for WOCBP. The topi[INVESTIGATOR_78609]:  
 Informed consent document  
 Pregnancy prevention information  
 Risks to unborn child(ren)  
 Any drug interactions with hormonal contraceptives  
 Contraceptives in current use  
 Guidelines for the follow -up of a reported pregnancy  
Prior to study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during 
participation in this clinical trial and the potential risk factors for an unintentional pregnancy. The subject 
must sign the informed consent document stating that the above -mentioned risk factors and the 
consequences were discussed with her.  
Height, Weight, Vital S igns: Height will be collected only at the Screening visit. Weight and vital signs 
(i.e., body temperature, respi[INVESTIGATOR_1487], sitting radial pulse ra te, and sitting systolic and diastolic blood 
pressures) will be obtained at the Screening, Injection Visit (pre - and post -treatment), Weeks 1, 2, 4, 8, 
and 16/Early Termination visits and at any visit where signs or symptoms of botulinum toxicity is 
report ed.   
12-Lead Electrocardiograms ( ECGs): At Screening, Week 2, and Week 16/Early Termination, a single 
standard supi[INVESTIGATOR_050] [ADDRESS_769140] 10 minutes. 
The ECG data  will be  submitted to a central reader for measurement.  Instructions for the collection, 
transmission, and archiving of the ECG data is ou tlined in the ECG central reader manual . The analyzed 
ECG data will be reviewed and signed by [CONTACT_737].  
X-rays:  X-rays of the affected foot is collected at Screening or prior to Injection visit. This procedure is 
to be done at individual study site. If subject(s) have had X -ray done within six (6) months prior to the 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version [ADDRESS_769141] ’s study information.      
Biological specimen collection and laboratory evaluations : As outlined in the Clinical Laboratory 
Tests table below, non -fasting samples for hematology, chemistry, and urinalysis will be collected at 
Screening, Week 2, and at Week 16/Early Termination visits.  
will be collected at Screening and Week 16/Early Termination visits. 
 
 Blood and urine will be collected using applicable safety 
precautions and will be processed according to the local clinical laboratory’s instructions.  
Clinical Laboratory Tests 
 
 
It is the Investigator’s responsibility to review the results of all laboratory tests as they become available. 
For each laboratory test result outside the reference range, the Investigator must ascertain if the abnormal 
lab result is a clinically significant result for that individual subject. Likewise, if laboratory tests are taken 
at follow-up visits, the Investigator must ascertain if this is an abnormal and clinically significant change 
pre-treatment for that individual subject. The Investigator may repeat the laboratory test or request 
additional tests to verify the results of the original laboratory test. The Investigator must sign and date all 
written laboratory results (e.g., urinalysis, hematology, chemistry, and pregnancy tests) and note Not 
Clinically Significant (NCS) or Clinically Significant (CS) for each out of range laboratory value. 
Toxicity grading for laboratory results is standardized using the FDA’s “Guidance for Industry: Toxicity 
Grading Scale for Health Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical 
Trials” dated September 2007. If a laboratory value is determined to be a clinically significant result for 
that subject, this may be considered an AE to be assessed according to severity. Refer to S ection 8.4  for 
further information . 
 
 
 
 Hematology Chemistry Urin alysis Additional Tests  
 Hemoglobin 
 Hematocrit  
 Leukocyte count (total)  
 Leukocyte count 
(differential)  
 Red blood cell count  
 Platelet count  
  Glucose 
 Total bilirubin 
 Alanine aminotransferase 
 Aspa rtate aminotransferase 
 Alkaline phosphatase  
 Blood urea nitrogen 
 Pregnancy (WOCBP at 
Scree ning) 
 Sodium 
 Potassium 
 Chloride  
 CO2 
 Creatinine 
 Calcium 
 Protein 
 Anion GAP 
 GFR   Speci fic gravity 
 pH 
 Glucose 
 Protein 
 Blood 
 Bilirubin 
 Ketones   
 
 
  
 
  
 
 
 
 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 34 Injection Site Evaluation:  The injection sites will be evaluated at Injection Visit (Day 0) pre- and post- 
treatment (to determine if the re is an immedia te reaction to the investiga tional product), follow-up visits 
(Weeks 1, 2, 4, 8 and 16 or Early Termination visit, if appli cable. The assessment will be done as a globa l 
evaluation of the inj ection sites. 
Injection Site Evaluation 
Assessment Descriptor  Present?  
 Yes No 
Erythema    
Edema    
Burning or Stinging (sensation as described by 
[CONTACT_1130])    
Itching (sensation as described by [CONTACT_1130])    
Bruising    
Drainage    
Foot and Ankle Examination:  Examination for the foot includes ankle, toe, and subtalar ran ge of 
motion, foot motor strength, lo cation of pain, and examination of the heel fat pad and Tine l’s si gn will be 
done at Screening, pre-treatment Injection, Weeks 1, 2, 4, 8, and 16/Early Termination visits. The 
presence of toe de formities, bunions, ul cers, and/or sores will be documented. The feet will be examined 
for signs of swelling, pi[INVESTIGATOR_13034], infection, or vascular abnormalities (refer to Appendix A ). 
Assessment of adverse events:  Adverse Events (AEs) will be graded as mild, moderate, or severe as 
defined in Section 8.4.[ADDRESS_769142]-treatment, follow-up Weeks 1, 2, 4, 8, and 16 or Early 
Termination visits, if applicable. Section 8.4.5  outlines the procedures for recording and reporting AEs. 
Adverse events will be reported by [CONTACT_585009] “21CRF p art 312.32 and Guidance for 
Industry and Inve stigators: Safety Rep orting Requir ements.”  The Inv estigator will report any serious 
adverse events ( SAEs) to the IRB. 
 
 
  
  
  
  
  
8.4 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
8.4.1  DEFINITION OF ADVERSE EVENTS (AE) 
For this protocol, an adverse event (AE)  is any untoward medical occurrence (e.g., sign, symptom, 
disease, syndrome, intercurrent illness, clinically significant abnormal laboratory finding, injury or 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  35 accident) that emerges or worsens following administration of investigational product and until  the end of 
trial participation that may not necessarily have a causal relationship to the administration of the 
investigational product. An AE can therefore be any unfavorable and/or unintended sign (including a 
clinically significant abnormal laboratory result), symptom, or disease temporally associated with the use 
of an investigational product, whether or not considered related to the investigational product. A 
treatment -emergent AE is one that occurs after any period of exposure to treatment.  
Pre-exist ing conditions, which increase in frequency or severity or a change in nature as a consequence of 
an investigational product use will also be considered an adverse event.  
An unexpected AE is an adverse reaction, the nature or severity of which is not consi stent with the 
applicable product information (e.g., Investigator’s Brochure for an unapproved investigational product or 
package insert/summary of product characteristics for an approved product).  
Any clinically significant change  in the study safety eval uations, (e.g., vital signs, laboratory results, 
ECG, injection site evaluation, physical/neurological examinations, etc.) post -treatment must be reported 
as an AE.  
8.4.2  DEFINITION OF SERIOU S ADVERSE EVENTS (SA E)  
A serious adverse event (SAE)  is any untoward m edical occurrence that results in any of the following 
outcomes:  
 Death  
 Life-threatening, (i.e., the subject was, in the opi[INVESTIGATOR_689], at immediate risk of 
death from the event as it occurred. It does not apply to an AE that hypothetically might have 
caused death if it were more severe)  
 Persistent or significant disability/incapacity or substantial disruption of the subject’s ability to 
carry out normal life functions  
 Requires in -patient hospi[INVESTIGATOR_34908] (i.e., a p rolonged hospi[INVESTIGATOR_396997]; hospi[INVESTIGATOR_86588]/surgical procedures, 
scheduled treatments, or routine check -ups are not SAEs by [CONTACT_44134])  
 Congenital anomaly/birth defect (i.e., an adverse outcome in a child or fetus of a subject exposed 
to the molecule or investigational product before conception or during pregnancy)  
 Does not meet any of the above serious criteria but based upon appropriate medical judgement 
may jeopardize the subject or may require m edical or surgical intervention to prevent one (1) of 
the outcomes listed above (i.e., is a significant or important medical event)  
8.4.3  CLASSIFICATION OF AN  ADVERSE E VENT  
[IP_ADDRESS]  SEVERITY OF EVENT  
The Investigator is responsible for evaluating all A Es and determining the severity of the event. Severity 
will be categorized as mild, moderate or severe according to the following definitions:  
 Mild:  Event may be noticeable to subject; does not influence daily activities; usually does not 
require intervention  
 Moderate:  Event  may be of sufficient severity to make subject uncomfortable; performance of 
daily activities may be influenced; intervention may be needed  
DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  36  Severe:  Event may cause severe discomfort; usually interferes with daily activities; subject may 
not be able to cont inue in the trial; treatment or other intervention usually needed  
[IP_ADDRESS]  RELATIONSHIP TO STUD Y INTERVENTION  
Relationship of an AE to investigational product will be assessed as follows:  
 Definite:  There is a clinically plausible time sequence between the onset of the AE and the 
administration of investigational product; when the event responds to withdrawal of 
investigational product and/or recurs with re -administration of investigational product  
 Probable:  There is a clinically plausible time sequence between the onset of the AE and the 
administration of investigational product; the AE is unlikely to be caused by [CONTACT_78654]/underlying illness, other drugs or procedures  
 Possible:  There may or ma y not be a clinically plausible time sequence between the onset of 
the AE and the administration of investigational product and a cause cannot be ruled out  
 Unrelated:  There is not a temporal or causal relationship to investigational product  
administration  
[IP_ADDRESS]  EXPECTEDNESS  
The Medical M onitor and Sponsor will be responsible for determining whether an adverse event ( AE) is 
expected or unexpected. An AE will be considered unexpected if the nature, severity, or frequency of the 
event is not consistent with the ris k information previously described for the study intervention . 
Expectedness is further  defined in the Investigator’s Brochure (IB)  under Anticipated Risks and Side 
Effects . The list of A Es found in the IB can be considered to be expected A Es.   
8.4.4  TIME PERIOD  AND FREQUENCY FOR EV ENT ASSESSMENT AND F OLLOW -
UP 
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention of 
study personnel during study visits and interviews of a study participant presenting for medical care, or 
upon review by a study monitor.  
All A Es including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate case report form (CRF). Information to be collected includes event description, time of onset, 
clinician’s assessment of severity, relationship to study product (assessed only by [CONTACT_10263] a diagnosis), and time of resolution/stabilization of the event. All A Es occurring 
while on study must be documented appropriately regardl ess of relationship. All A Es will be followed to 
adequate resolution.  
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition  deteriorates at any time 
during the study, it will be recorded as an AE.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed. A Es characterized as intermittent require documentation of 
onset and duration of each epi[INVESTIGATOR_1865].  
The I nvestigator or study staff  will record all reportable events with start dates occurring any time after 
informed consent is obtained until 7 (for non -serious A Es) or 30 days (for SAEs) after the last day of 
study participat ion. At each study visit, the I nvestigator or study staff will inquire about the occurrence of 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  37 AE/SAEs s ince the last visit. Events will be followed for outcome information until resolution or 
stabilization.  
8.4.[ADDRESS_769143] -treatment and at each subsequent trial visit for the occurrence of 
AEs. In order to avoid bias in eliciting A Es, subjects should be asked the following non leading question: 
“How have you felt since your last visit?” All A Es (serious and non -serious) reported by [CONTACT_585010].  
In addition, an Investigator must report an SAE to Revance within [ADDRESS_769144] report an SAE to Revance or the desig nated CRO’s authorized representative within 
24 hours  of their awareness of the event:  
 Complete and return an SAE Form with all information known to date; including the 
Investigator’s assessment of causality.  
 If the event is fatal or life -threatening, telephone Revance or the authorized representative as 
soon as the Investigator learns of the event.  
 Obtain and maintain all pertinent medical records (discharge summary, autopsy report, etc.) 
and medical judgments  of medical personnel who assisted in subject’s treatment and follow -
up. 
 Provide follow -up information to Revance or the authorized representative.  
All SAEs will be followed until satisfactor y resolution or until the I nvestigator deems the event to be 
chronic or the participant is stable. Other supporting documentation of the event may be requested by [CONTACT_181110] (DCC)/study sponsor and should be provided as soon as possible.  
The study sponsor will be responsible for notifying the Food and Drug Administration (FDA) of any 
unexpected fatal or life -threatening suspected adverse reaction as soon as possible, but in no case later 
than 7 calendar days after the sponsor ’s initi al receipt of the information. In addition, the sponsor must 
notify FDA and all participating i nvestigators in an Investigational New Drug (IND) safety report of 
potential serious risks, from clinical trials or any other source, as soon as possible, but in no case later 
than 15 calendar days after the sponsor determines t hat the information qualifies for reporting.  
Regulatory authorities, IRBs/IEC, and Investigators will be notified of SAEs in accordance with 
applicable regulations and requirements (e.g., GCPs, ICH Guidelines, national regulations and local 
requirements).  
8.4.[ADDRESS_769145] scheduled trial visit (or early discontinuation, if 
applicable) must be recorded on the AE CRF as ongoing.  
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version [ADDRESS_769146] results, e.g., laboratory findings, at the Week 16/Early 
Termination visit should be followed to resolution or until determined by [CONTACT_585011]. 
Repeat tests may be indicated to establish this. 
If a subject has any clinically significant, trial-related abnormalities at the end of the trial, the Medical 
Monitor should be notified and every effort made by [CONTACT_585012]. 
8.4.[ADDRESS_769147] (or early discontinuation, if applicable) must be 
recorded on the AE CRF page and reported to the CRO and Revance according to the reporting 
procedures outlined in Section 8.4.6. This may include unresolved previously reported SAEs, or new 
SAEs. The Investigator should follow these SAEs until the events are resolved, or the subject is lost to 
follow-up. The Investigator should continue to report any significant follow-up information to the 
Medical Monitor, Revance, and the IRB/IEC up to the point the event has been resolved. Resolution 
means the subject has returned to the baseline state of health, or the Investigator does not expect any 
further improvement or worsening of the subject’s condition.  
Any new SAEs reported by [CONTACT_585013]/IEC. 
  
 
 
 
  
 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
  

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version [ADDRESS_769148] the Investigator immediately (within 24 
hours) if they suspect they might be pregnant (e.g., missed or late menstrual cycle). The Investigator must 
immediately notify Revance or designated Contract Research Organ ization (CRO) of any female subject 
who becomes pregnant any time during study participation, record the information on the Pregnancy 
Notification Form and send the form to the CRO. The site will be asked to follow -up with the subject 
periodically during t he pregnancy for ongoing health and safety information through term, as applicable. 
Subjects will remain on the trial. 
8.5 UNANTICIPATED  ADVERSE EVENTS  
8.5.1  DEFINITION OF U NANTICIPATED ADVERSE EVENTS  
 
The Office for Human Research Protections ( OHRP) considers unanticipated problems involving risks to 
participants or others to include, in general, any incident, experience, or outcome that meets all of the 
following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the rese arch procedures that are 
described in the protocol -related documents, such as the Institutional Review Board (IRB) -
approved research protocol and informed consent document; and (b) the characteristics of the 
participant population being studied;  
• Related or  possibly related to participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_9156]); and  
• Suggests that the research places  participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was  previously known or recognized  
Revance will comply with these criteria for reporting Unanticipated Adverse Events . 
8.5.[ADDRESS_769149] 
(IRB) and the Sponsor.  The unanticipated adverse event  report will include the following information:  
• Protocol identifying inform ation: protocol title and number, PI’s name, and the IRB project 
number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an unan ticipated adverse event ;  
• A description of any changes to the protocol  by [CONTACT_585014] . 
• The Sponsor will update the IB or provide Dear Doctor let ter should these actions be deemed 
required.  
To satisfy the requirement for prompt reporting, unanticipated adverse events  will be reported using the 
following timeline:   
 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  41 • Unanticipated adverse events  that are  fatal and life -threatening  serious adverse events (SAEs) will 
be reported to the IRB and to the Sponsor within seven (7) days  of the I nvestigator becoming 
aware of the event.  
• Any other unanticipated adverse event s that are SAEs will be reported to the IRB and to the 
Sponsor  within 15 days  of the I nvestigator becoming aware of the problem.  
• All unanticipated adverse events that non -serious A Es are not required to be reported to the IRB 
or to the Sponsor.  
• All unanticipated serious adverse events  should be reported to appropri ate institutional officials 
(as required by [CONTACT_17347]’s written reporting procedures), the supporting agency head (or 
designee), and the Office for Human Research Protections (OHRP) if applicable.  
8.5.3  REPORTING UNANTICIPA TED ADVERSE EVENTS  TO PARTICIPANT S  
Revance will disclose clinical trial data to individuals, to investigators at clinical sites, and publicly as 
aggregate summaries, in accordance to Regulatory and local legal requirements.  
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 42 9 STATISTICAL CONSIDER ATIONS   
9.1 STATISTICAL HYPOTHES IS 
Treatment with DaxibotulinumtoxinA for Injection of plantar fascia and plantar muscles combined with 
transient and selective partial paralysis of gastrocnemius/soleus complex (dysfunction) and a simple home 
program and inexpensive splinting will ameliorate signs and symptoms of plantar fasciitis; will improve 
function, and will optimize health related quality of life.  
9.2 SAMPLE SIZE DETERMIN ATION  
With a total of 60 subjects (30 per group) and assuming a drop-out rate of no more than 20%,  
 
 
 
 
 
 
 
 
 
 
9.3 POPULATIONS FOR ANALYSES  
Approximately 60 subjects, 18-65 years of age, will be randomized in a 1:1 ratio to re ceive inj ections of 
either active (DaxibotulinumtoxinA for Injection) or placebo.  
 
 
9.4 STATISTICAL ANALYSES  
9.4.1  GENERAL APPROACH 
All evaluable efficacy data will be included in the analysis following the intent- to-treat (ITT) principle. 
All subjects who received the study treatment (DaxibotulinumtoxinA for Injection or placebo) will 
comprise the modified- ITT population and will be grouped according to each subject’ s randomization 
assignment. The primary analysis will focus on the reduction from baseline in the VAS for pain at eight 
(8) weeks with missing data imputed by [CONTACT_585015], that 
is, the last-observation- carried-forward (LOCF) approach. Analysis of covariate (ANCOVA) model 
including treatment group as a factor and baseline pain score as a covariate will be used. 
Reductions from baseline VAS for pain for the foot over time up to eight (8) weeks will also be analyzed 
using a statistical method that handles repeated measures such as a generalized linear model (GLM) 
including treatment group, time (visit) and the treatment-visit interaction term as factors and the baseline 
VAS for pain as a covariates. For other secondary and exploratory efficacy outcome measures, 
appropriate statistical models (e.g., ANCOVA or GLM for continuous variables, and chi- squared/Fisher’s 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version [ADDRESS_769150] or logistic regression for dichotomy or categorical variables) adjusting for relevant covariates 
will be employed to evaluate the treatment effect. 
As a sensitivity analysis to check the impact of major protocol violations to study results, the primary and 
secondary efficacy outcome measures will also be analyzed on data from all subjects in per-protocol (PP) 
population, which consists of subjects in the modified-ITT population who do not have any major 
protocol violations. To check the robustness of results using the LOCF approach, different methods (such 
as observed data only or multiple imputation) may be employed to handle missing data when appropriate. 
As an exploratory analysis, proportion of subjects achieving certain status defined by [CONTACT_585016] (e.g., having a reduction in the VAS for pain by a certain clinical meaning cut-point) will 
also be compared between treatment groups. 
Safety data from all subjects who received study treatment will be summarized with subjects being 
grouped based on the treatment each subject actually received.  
9.4.2  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
The primary endpoint is: 
 Reduction in the visual analog scale (VAS) for pain for the foot at Week 8 
Analysis of the primary efficacy endpoint is fully defined in the statistical analysis plan.  
3  
  
  
  
  
  
 
  
4  
 
 
 
 
 
 
 
 
  
 
 
 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 44 6  
 
 
 
 
 
 
 
 
 
  
 
 
7  
  
  
 
9  
 
  
   
 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  45 10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS  
10.1 REGULATORY, ETHICA L, AND STUDY OVERSIGHT CONSIDERATIONS  
10.1.1  INFORMED CONSENT PRO CESS  
[IP_ADDRESS]  INFORMED CONSENT AND  AUTHORIZATION TO RELEASE HEALTH 
INFORMATION  
Written informed consent will be obtained from all subjects before any study -related procedures 
(including any screening procedures) are performed. The Investigator may discuss the trial and the 
possibility for entry with a po tential subject without first obtaining consent. However, a subject wishing 
to participate must give written informed consent prior to any study -related procedures being conducted, 
including those performed solely for the purpose of determining eligibility  for study participation, and 
including withdrawal from current medication (if required prior to study entry). The Investigator has both 
the ethical and legal responsibility to ensure that each subject being considered for inclusion in this trial 
has been given a full explanation of the procedures and expectations for study participation.  
The site -specific informed consent must be forwarded to Revance for approval prior to submission to an 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) that is registered with the US 
Department of Health and Human Services (HHS) or applicable health authority. Each subject will sign 
the consent form that has been approved by [CONTACT_78626]/IEC that was responsible for protocol approval. 
Each informed consen t document must adhere to the ethical principles stated in the Declaration of 
Helsinki and will include the elements required by [CONTACT_235794] 21 CFR Part  50, as well as the 
elements required by [CONTACT_585017] (ICH) Good C linical Practice (GCP) 
guideline, and applicable federal and local regulatory requirements. The consent form must also include a 
statement that Revance, their designees, and auditing regulatory agencies will have direct access to the 
subject’s records and medical history for study related purposes.  
Once the appropriate essential information has been provided to the subject and fully explained by [CONTACT_3786] (or a qualified designee) and it is felt that the subject understands the implications and risks  
of participating in the trial, the IRB/IEC approved consent document shall be signed and dated by [CONTACT_245751] (Investigator or designee), and by [CONTACT_585018]/IEC or other regulatory authoritie s. The subject will be given a copy of the signed informed 
consent document with the original kept on file by [CONTACT_737]. All of the above activities must be 
completed before any study related procedures are conducted (including a ny screening study p rocedures).  
[IP_ADDRESS]  CONSENT PROCEDURES A ND DOCUMENTATION  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study 
and continues throughout the individual’s study participation.  Consent forms will be Institutional Review 
Board ( IRB)-approved and the participant will be asked to read and review the document. The 
Investigator will explain the research study to the participant and answer any questions that may arise. A 
verbal explanation will be provided in terms suited to the participant’s comprehension of the purposes, 
procedures, and potential risks of the study and of their rights as research participants. Participants will 
have the opportunity to carefully review the written consent form and ask quest ions prior to signing.  The 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version [ADDRESS_769151] be informed that participation is 
voluntary and that they may withdraw from the study at any time, without prejudice. A copy of the 
informed consent document will be given to the participants for their records. The informed consent 
process will be conducted and documented in the source document (including the date), and the form 
signed, before the participant undergoes any study-specific procedures. The rights and welfare of the 
participants will be protected by [CONTACT_132441].] 
10.1.2  STUDY DISCONTINUATION AND CLOSURE 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause. Written notification, documenting the reason for study suspension or termination, will be provided 
by [CONTACT_21224], investigators, the Investigational New Drug 
(IND) sponsor and regulatory authorities. If the study is prematurely terminated or suspended, the 
Principal Investigator (PI) will promptly inform study participants, the Institutional Review Board (IRB), 
and sponsor and will provide the reason(s) for the termination or suspension. Study participants will be 
contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule. 
Circumstances that may warrant termination or suspension include, but are not limited to: 
 Determination of unexpected, significant, or unacceptable risk to participants 
 Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]  
 Insufficient compliance to protocol requirements 
 Data that are not sufficiently complete and/or evaluable 
 Determination that the primary endpoint has been met 
 Determination of futility 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, and 
satisfy the sponsor, IRB and/or Food and Drug Administration (FDA). 
  
 
 
 
 
 
 
  
 
 
  
 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 47  
 
 
 
 
  
  
 
  
 
 
  
  
   
 
  
  
  
10.1.6    SAFETY MONITORING/DATA MANAGEMENT COMMITTEE 
An independent Data Management Committee (DMC) will be appointed to review safety data during the 
study. Details of the composition and scope of the committee’s mandate will be presented in a DMC 
Charter document. Following recruitment of all subjects, the DMC will evaluate all safety data available 
at timepoints specified in the Charter, and will make appropriate recommendations.  
10.1.7  MONITORING, COMPLIANCE, AND QUALITY 
All aspects of the trial will be monitored by [CONTACT_585019] (GCP) and Standard Operating Procedures (SOPs) for compliance with 
applicable government regulations, (i.e., Informed Consent Regulations and Institutional Review Board 
regulations).  
 
 
 
 
 
 
 
 
 
 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version [ADDRESS_769152] KEEPI[INVESTIGATOR_1645]  
[IP_ADDRESS] DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
[IP_ADDRESS].[ADDRESS_769153]’s  completion of the trial, the Investigator will sign a statement indicating that 
all pages of the subject’s case report have been reviewed. Signature [CONTACT_78670] “per signatures” are not 
acceptable.  
It is Revance’s policy that the trial data be verifiable with the source data that necessitates access to all 
original recordings, laboratory reports, and other records for each subject. The Investigator must therefore 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  49 agree to allow access to subjects’ records, and source data must be made available for all trial data. 
Subjects (or their legal representatives) must also allow access to their medical records. Subjects will be 
informed of the importance of increased record access and permission granted by [CONTACT_585020]. 
Checks will be performed to ensure the quality, consistency, and completeness of the data. Instances of 
missing or un -interpretable data will be resolved with the Investigator or Study Coordinator. Data queries 
will be sent to the trial center. Site pe rsonnel will be responsible for providing resolutions to the data 
queries and for correcting the CRFs, as appropriate. All unused Revance source documents and binders 
must be returned to Revance upon completion of the trial. 
The Investigator must keep writ ten or electronic source documents for every subject participating in the 
clinical trial. The subject file that identifies the study in which the subject is participating must include the 
subject’s available demographic and medical information including:  
 Date of birth  
 Sex 
 Race  
 Ethnicity  
 Medical history  
 Comorbid conditions  
 Concomitant therapi[INVESTIGATOR_014]/medication  
 Study visit dates  
 Performed examinations, evaluations, and clinical findings  
 Investigational product administration  
 AEs, SAEs, or pregnancy (as applicable)  
Additionally, any other documents with source data, especially original printouts of data that were 
generated by [CONTACT_78665]’s source document (e.g., laboratory 
value listings). All these documents must h ave at least the subject’s initials, trial number, and the date of 
the evaluation.  
The data recorded during the course of the trial will be documented in the CRF and/or the trial -specific 
forms. Before or at study termination, all data must be forwarded t o Revance. The data will then be 
recorded, evaluated, and stored in anonymous form in accordance with data -protection regulations.  
Subjects will authorize the use of their protected health information during the informed consent process 
in accordance with the applicable privacy requirements. Subjects who deny permission to use and 
disclose protected health information will not be eligible to participate in the trial. The Investigator will 
ensure that the trial documents forwarded to Revance, and any other d ocuments, contain no mention of 
subject names.  
Any amendments and corrections necessary will be undertaken in both the source documents and CRFs 
(as appropriate) and countersigned by [CONTACT_737], or documented designee, stating the date of the 
amendme nt/correction. Errors must remain legible and may not be deleted with correction aids. The 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment [ADDRESS_769154] state his/her reason for the correction of any data. In the case of missing data/remarks, 
the entry spaces provided in the CRF should be cancelled out so as to avoid unnecessary follow -up 
inquiries.  
Regulatory authorities, the IRB/IEC and/or the Revance’s Quality Assurance group (or designee) may 
request access to all source documents, CRFs, and other trial documentation for on -site audit or 
inspecti on. The Investigator must guarantee direct access to these documents. CRFs will be kept by 
[CONTACT_235816] a secured area. Clinical data will be recorded in a computer format 
for subsequent statistical analyses. Data files will be stor ed on electronic media with a final master data 
file kept by [CONTACT_585021].  
[IP_ADDRESS].2  FILE MANAGEMENT AT T HE TRIAL CENTER  
It is the responsibility of the Investigator to ensure that the trial center file is maintained in accordance 
with ICH Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance, Section 8 – Essential 
Documents for the Conduct of a Clinical Trial.  Documentation  is subje ct to insp ection by [CONTACT_585022]. 
[IP_ADDRESS]  RECORDS RETENTION AT  THE TRIAL CENTER  
It is a  sponsor  requirement that all Investigators participating  in clinical studi es maintain d etailed clinical 
data for one (1) of the  following  periods:  
 Country -specific requirements, or  
 A period of at least two (2)  years following the last approval of a marketing application approved 
by a Regulatory Authority in an ICH region or until there are no pending or contemplated 
marketing applications in an ICH region, or,  
 A period of two (2) years after Revance notifies the Investigator that the data will not be 
submitted for review by [CONTACT_34699]  
[IP_ADDRESS]  TREATMENT OF MISSING  DATA  
Some d ata elements will be  missing  in this s tudy due to subje cts who withdr aw from the  study, subjects 
who are lost to follow -up, or subjects who do not complete  all stu dy visits. The  compl etion st atus of each 
subject will be  document ed (e.g., compl eted p rotocol, wit hdrew from stu dy, lost to follow-up, etc.). All 
reasonable efforts will be  made  by [CONTACT_585023] d uring 
their participation in the  study. The  study coordin ator will attempt to contact [CONTACT_585024] -up. For subj ects who are unwilling  to return to  clinic for follow-up, the  study coordi nator will 
attempt to contact [CONTACT_585025] a telephone  call or by [CONTACT_585026] m ail. 
10.1.[ADDRESS_769155] requires immediate intervention, based on the judgment 
of the Investigator (or a responsible, appropriately t rained professional designated by [CONTACT_737]). In 
the event of a significant deviation from the protocol due to an emergency, accident, or mistake, the 
Investigator or designee must contact [CONTACT_235803]. This wil l allow 
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version [ADDRESS_769156]’s continuation in the trial. This decision will be documented 
by [CONTACT_2725]. 
  
 
 
 
 
  
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
10.[ADDRESS_769157] be conducted in compliance with the protocol, the ICH Guidance for Industry E6 Good 
Clinical Practice: Consolidated Guidance and the applicable regulatory requirements. Investigators must 
submit all essential regulatory documentation, as required by [CONTACT_27952] (including 
approval of the protocol and informed consent form by [CONTACT_245761]-registered IRB/IEC) to Revance before 
investigational product will be shipped to the study site. 
 
 
 
 
 
 
 
 
 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 52  
 
 
 
 
  
  
  
 
 
  

DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment 3  
Protocol 1720201   14 Dec  2017  
Revance Therapeutics, Inc.  Confidential  53 10.3 ABBREVIATIONS  
 
AE Adverse Event  
ANCOVA  Analysis of Covariance  
AOFAS  American Orthopaedic Foot and Ankle Score  
BoNTA  Botulinum Toxin Type A  
BP Blood Pressure  
CFR  Code of Federal Regulations  
cm Centimeter  
CRF  Case Report Form  
CS Clinical Significant  
DMC  Data M anagement Committee  
EC Ethics Committee  
ECG  Electrocardiogram  
FADI  Foot and Ankle Disability Index  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practices  
GMP  Good Manufacturing Practices  
HHS  Health and Human Services  
HR Heart Rate  
IB Investigator’s Brochure  
ICH International Council for  Harmonisation   
IM Intramuscular(ly)  
in Inch 
IND Investigational New Drug Application  
IRB Institutional  Review Board  
ITT Intention -To-Treat  
kDA  Kilodalton  
MedDRA  Medical Dictionary for Regulatory Activities  
mL Milliliter  
mm Millimeter  
msec  Millisecond  
NCS  Not Clinically Significant  
ng Nanogram  
NIH  National Institutes of Health  
OHRP  Office for Human Research Protections  
PFPS  Plantar Fasciitis Pain and Disability Scale  
PP Per Protocol  
PROMIS  Patient Reported Outcome Measurement Information System  
QT Measurement of time between start of the q wave and the end of the t wave in the heart’s 
electrical conduction  
QTc Corrected QT interval; represents electrical systole  
Revance  Revance Therapeutics, Inc . 
RT002  DaxibotulinumtoxinA for Injection  
RTP004  Revance absorption enhance pep tide 
SAE  Serious Adverse Event  
SC Subcutaneous  
DaxibotulinumtoxinA for Injection for Plantar Fasciitis  Version 4.0, Amendment [ADDRESS_769158]  
TdP Torsade de Pointe  
U Units (botulinum toxin)  
UA Urinalysis  
UPT  Urine Pregnancy Test  
US [LOCATION_002]  of America  
VAS  Visual Analog Scale  
WFBMC  Wake Forest Baptist Medical Center  
WOCBP  Women of Child -Bearing Potential  
 
  
DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 55 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 56 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 57 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 58 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 59 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 60 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 61 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 62  

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 63  

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 64 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 65                                     

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 66                                                  
                                              
                                                                
                                                

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 67 

DaxibotulinumtoxinA for Injection for Plantar Fasciitis Version 4 .0, Amendment 3 
Protocol 1720201  14 Dec 2017  
Revance Therapeutics, Inc. Confidential 68 
